GSK's clinical-stage pipeline is currently focused on oncology, respiratory, immunology and inflammation, and infectious ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...

In chronic myelogenous leukaemia (CML), a reciprocal translocation between chromosomes 9 and 22 results in a gene encoding BCR–ABL, a fused deregulated kinase that stimulates cellular ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

ABL has data showing that ABL301 can penetrate ... as well as a now-defunct alliance between AbbVie and Voyager in 2019, based on gene therapy approaches to target the rogue protein.

The structural basis for imatinib resistance in chronic myeloid leukaemia (CML) involves the emergence of imatinib-resistant BCR-ABL point mutations; mutations are usually those that impair drug ...

GSK pays ABL Bio $49.5M upfront for blood-brain barrier platform access, with potential $2.67B in milestone payments. Deal focuses on developing neurodegenerative disease treatments.